|
|
30-40 Flockhart Street
Abbotsford, Victoria 3067 Australia
phone:+61 (0) 3 8420 7300
fax:+61 (0) 3 8420 7399
|
|
| Symbol |
CMP.ASX |
| Exchange |
ASX |
| Founded |
1987 |
| Employees |
130 |
|
|
| www.compumedics.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Computer based diagnostic technologies in the areas of sleep, Neurology and Cardiology. |
|
| Management |
| Dr. David Burton, Executive Chairman CEO; Mr. Alan Anderson, Non-Executive Director; Professor Graham Mitchell AO, Non-Executive Director; Mr. David Lawson, CFO & Company Secretary; Mr. Warwick Freeman, CTO; Mr. Christoph Witte, General Managing Director DWL Compumedics Germany GmbH; |
| |
|
|
|
|
|
|
|
| Keywords |
| sleep, neurology, cardiology, diagnostic technologies, epilepsy, monitoring, sleep therapy, |
|
|
|
| Description |
|
Compumedics' core business is the development and commercialization of technology with a focus on the fast growing Sleep Medicine and Neurology markets.
Strategic alliance / investor opportunities are being sought for Compumedics / DWL unique patented AF ablation emboli detection and containment technology; unique patented sleep treatment technology (SPAP®).
Compumedics leads the sleep diagnostic market in Australia, with a market share of approximately 80%, and a growing international business, especially in the USA, which is the world’s largest medical device market.
The company is currently expanding its global sales force 2-3 fold to compliment its existing sleep diagnostic and neurology technological leadership. |
|
| Products / Services |
- Sleep Diagnostic Systems (GraelHD, SomtePSG, Siesta802)
- Laboratory based, ambulatory and portable
- Home Sleep Testing systems
- Sleep Therapy Devices (Somnilink SPAP)
- Epilepsy Monitoring Systems (GraelHD, NeuvoLTM, Siesta802)
- Brain research products (CURRY, Maglink, SynAmpsRT)
- Ultrasound Brain Bloodflow Devices (DWL)
|
|
| Technology / Differentiation |
| Compumedics is a multi-award winning company and differentiates itself on its innovative strengths, complete range from clinical to research devices, active involvement in the sciences and an extensive premiere client base globally. |
|
| Market / Customers |
- Hospitals, Clinics, Research Institutions, Universities, Epilepsy Monitoring Units, Sleep Labs
- Investor Statement
- Compumedics Limited is an Australia-based company that develops, manufactures, and distributes world-wide its technologically advanced products in the fields of sleep diagnostics, neurological diagnostics, and Doppler ultrasound blood-flow monitoring.
- Compumedics® represents a brand of superior technology selected by top research laboratories and clinics world-wide.
- The company has subsidiaries in the USA and Germany with local representation and expertise, and representatives or distributors for the significant Chinese and Japanese markets. The three business divisions generate annual revenues in excess of $30 million, with leading market shares in each territory. The company has continued to invest in new product development throughout its history and is poised for its next growth stage with enhanced sleep-diagnostics products, long-term electroencephalography products, and next generation sleep-treatment products.
- The new products will address significant markets, each of which represents opportunities in the order of $2-3 billion and growing quickly.
In particular, a significant proportion of the world-wide population has undiagnosed sleep disorders that lead to treatment needs.
- The new products make diagnosis easier and lead to better treatment outcomes.
|
|
| Strategy |
The company is currently expanding its global sales force 2-3 fold to compliment its existing sleep diagnostic and neurology technological leadership.
Additionally, Compumedics is focussed on growth through strategic alliances, designed to further realise the Company's valuable technology and intellectual property folios.
Strategic alliance opportunities include strategic investment or other OEM or license agreements to further commercialize Compumedics' sleep, neurology and ultrasonic blood-flow products or intellectual property.
Alliance is being sought in key market niches such as transcranial Doppler solid versus gaseous emboli detection and containment during AF ablation, heart valve or vascular stent procedures. Additionally, alliances are being sought in order to commercialize Compumedics' folio of sleep treatment products and intellectual property.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members